Related Experiment Video
Updated: Feb 10, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Molecular diagnostics and personalized medicine: value-assessed opportunities for multiple stakeholders
1Integrated Medicines Ltd, Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK. eddie.blair@integratedmedicines.co.uk.
Abstract:
Acceptance and operation of a personalized medicine strategy within modern healthcare requires that all key stakeholders are able to understand and assess the benefits offered by the approach. In addition to the technological aspects of molecular diagnostics, as enablers of personalized medicine, stakeholders must also be apprised of the value-adding effects of the strategy in terms of improved treatment efficacy and health economics. This review attempts to cover these broad stakeholder interests by articulating the scientific feasibility, the beneficial medical outcomes and the commercial attractiveness offered by the integration of molecular diagnostics and personalized medicine into healthcare systems, principally by demonstrating how technology integration and value addition can be robustly assessed and represented.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Multiple Allele Traits
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Microorganisms in Medicine and Therapeutics
Molecular Models
Personal Identity

